Michael P. Bailey
Net Worth
Last updated:
What is Michael P. Bailey net worth?
The estimated net worth of Mr. Michael P. Bailey is at least $14,068,339 as of 20 Dec 2022. He has earned $28,339 from insider trading and has received compensation worth at least $14,040,000 in AVEO Pharmaceuticals, Inc..
What is the salary of Michael P. Bailey?
Mr. Michael P. Bailey salary is $1,080,000 per year as Chief Executive Officer, Pres & Director in AVEO Pharmaceuticals, Inc..
How old is Michael P. Bailey?
Mr. Michael P. Bailey is 60 years old, born in 1965.
What stocks does Michael P. Bailey currently own?
As insider, Mr. Michael P. Bailey owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| AVEO Pharmaceuticals, Inc. (AVEO) | Chief Executive Officer, Pres & Director | 49,311 | $0 | $0 |
What does AVEO Pharmaceuticals, Inc. do?
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Michael P. Bailey insider trading
AVEO Pharmaceuticals, Inc.
Mr. Michael P. Bailey has made 4 insider trades between 2012-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 164,525 units of AVEO stock on 20 Dec 2022. As of 20 Dec 2022 he still owns at least 49,311 units of AVEO stock.
AVEO Pharmaceuticals key executives
AVEO Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Mr. Michael P. Bailey (60) Chief Executive Officer, Pres & Director